Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark G Lebwohl

Showing results (201-210 of 209) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 209 results.
Journal of the American Academy of Dermatology|January 22, 2018
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trialEmma Guttman-Yassky, Patrick M Brunner, Avidan U Neumann, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 22, 2023
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III StudyKim A Papp, Mark G Lebwohl, Diamant Thaçi, et al.
The Journal of Clinical Investigation|July 1, 2025
Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flaresJames G Krueger, Mrinal K Sarkar, Mark G Lebwohl, et al.
The Journal of Allergy and Clinical Immunology|August 20, 2018
Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumabPatrick M Brunner, Ana B Pavel, Saakshi Khattri, et al.
JAMA|September 20, 2022
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical TrialsMark G Lebwohl, Leon H Kircik, Angela Y Moore, et al.
Archives of Dermatology|January 18, 2012
Consensus guidelines for the management of plaque psoriasisSylvia Hsu, Kim Alexander Papp, Mark G Lebwohl, et al.
The Journal of Investigative Dermatology|February 14, 2014
Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable diseaseShanthi Sivendran, Rui Chang, Lisa Pham, et al.
Journal of the American Academy of Dermatology|December 3, 2016
From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasisApril W Armstrong, Michael P Siegel, Jerry Bagel, et al.
JAMA Dermatology|June 18, 2025
Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis FoundationApril W Armstrong, George C Gondo, Joseph F Merola, et al.
Pageof 21

Showing results (201-210 of 209) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 209 results.
Journal of the American Academy of Dermatology|January 22, 2018
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trialEmma Guttman-Yassky, Patrick M Brunner, Avidan U Neumann, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 22, 2023
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III StudyKim A Papp, Mark G Lebwohl, Diamant Thaçi, et al.
The Journal of Clinical Investigation|July 1, 2025
Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flaresJames G Krueger, Mrinal K Sarkar, Mark G Lebwohl, et al.
The Journal of Allergy and Clinical Immunology|August 20, 2018
Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumabPatrick M Brunner, Ana B Pavel, Saakshi Khattri, et al.
JAMA|September 20, 2022
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical TrialsMark G Lebwohl, Leon H Kircik, Angela Y Moore, et al.
Archives of Dermatology|January 18, 2012
Consensus guidelines for the management of plaque psoriasisSylvia Hsu, Kim Alexander Papp, Mark G Lebwohl, et al.
The Journal of Investigative Dermatology|February 14, 2014
Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable diseaseShanthi Sivendran, Rui Chang, Lisa Pham, et al.
Journal of the American Academy of Dermatology|December 3, 2016
From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasisApril W Armstrong, Michael P Siegel, Jerry Bagel, et al.
JAMA Dermatology|June 18, 2025
Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis FoundationApril W Armstrong, George C Gondo, Joseph F Merola, et al.
Pageof 21